Daniil Gataulin

Mayank Mamtani

Jay Olson

Raghuram Selvaraju

Ram Selvaraju

- Zervimesine (CT1812) is advancing towards Phase 3, with the FDA aligning on the Phase 3 design for mild-to-moderate Alzheimer's disease, targeting patients with p-tau217 at screening ≤ **1.0 pg/mL**.  **[1455365_0001104659-25-089737_tm2525997d1_ex99-1.htm:1]** **[1455365_0001104659-25-089737_tm2525997d1_ex99-1.htm:6]** 
- Phase 2 studies demonstrated consistent efficacy signals for zervimesine in Alzheimer's disease (SHINE study), Dementia with Lewy Bodies (SHIMMER study), and dry age-related macular degeneration (MAGNIFY study).  **[1455365_0001104659-25-089737_tm2525997d1_ex99-1.htm:4]** **[1455365_0001104659-25-089737_tm2525997d1_ex99-1.htm:7]**   
- The company reported a favorable safety and tolerability profile for zervimesine across all studies, with over **450 people** treated to date.  **[1455365_0001104659-25-089737_tm2525997d1_ex99-1.htm:4]**     
- Cognition Therapeutics closed a **$30 million** equity raise in August 2025.   
- As of **June 30, 2025**, the company's financial position was:
| Metric | Q2 2025 |
|---|---|
| Cash and cash equivalents ($USD Millions) | **$11.6**    |
| Remaining grant funding ($USD Millions) | **$42**    |

Cognition Therapeutics Provides Update on Zervimesine Clinical Programs and Financial Position

- Cognition Therapeutics (CGTX) **closed a registered direct offering** on **September 2, 2025**.  **[1455365_00e8e8d6498f49618462707596286abb_0]** 
- The offering generated approximately **$30 million** in gross proceeds from the sale of **14,700,000 shares** of common stock at a purchase price of **$2.05 per share**.  **[1455365_00e8e8d6498f49618462707596286abb_0]** 
- The company intends to use the additional capital to **advance zervimesine** for the treatment of serious neurodegenerative disorders.  **[1455365_00e8e8d6498f49618462707596286abb_0]**

COGNITION THERAPEUTICS (CGTX)